ASH 2018 | PD-1 & PDL-1 combinations with CAR T-cell therapy

David Maloney

David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA., discusses the safety and efficacy regarding the combination of various agents with CAR T-cell therapy, notably checkpoint inhibitors for PD-1 and PDL-1, which offer a bright future for those who relapse after CAR T-cell therapy, though it is still early days. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video